NCT06534268

Brief Summary

This study employs a prospective, single-center, open, observational research design to evaluate postoperative adrenal cortical function in patients with primary aldosteronism (PA) and to explore indicators predicting postoperative adrenal insufficiency and their predictive efficacy

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
2mo left

Started Aug 2024

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress91%
Aug 2024Jul 2026

First Submitted

Initial submission to the registry

July 27, 2024

Completed
6 days until next milestone

First Posted

Study publicly available on registry

August 2, 2024

Completed
13 days until next milestone

Study Start

First participant enrolled

August 15, 2024

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 15, 2026

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 30, 2026

Expected
Last Updated

August 2, 2024

Status Verified

July 1, 2024

Enrollment Period

1.6 years

First QC Date

July 27, 2024

Last Update Submit

August 1, 2024

Conditions

Outcome Measures

Primary Outcomes (10)

  • The gender and age of the participants

    age in years and sex (female or male) of patients

    1 day

  • Participant's weight and height

    BMI(body mess index) in kg/m\^2= (weight in kg) /(height in m)\^2

    1 day

  • Patients' baseline hormone level

    serum hormone level

    1day

  • Number of Participants with baseline glucose metabolic levels

    glucose metabolism, lipid metabolism, liver and kidney function, electrolytes, etc

    1 day

  • Patients' hormone levels at 0 minutes and 120 minutes after preoperative ACTH stimulation test

    cortisol and aldosterone levels

    1day

  • Patients' hormone levels at 0 minutes and 120 minutes after postoperative ACTH stimulation test

    cortisol and aldosterone levels

    1day

  • Number of Participants with baseline lipid metabolic levels

    blood lipid levels

    1day

  • Patients' baseline glucose metabolic levels

    0-minute、30-minute、60-minute 、120-minute and 180-minute blood glucose levels after OGTT

    1day

  • Number of Participants with baseline electrolytes levels

    sodium, potassium, chloride, calcium, and phosphorus ion levels

    1day

  • Number of Participants with baseline kidney function levels

    Creatinine, blood urea nitrogen (BUN), and uric acid levels

    1day

Secondary Outcomes (4)

  • the changes of hormone levels after surgical management

    1day

  • Number of Participants with changes of lipid metabolic levels after surgical management

    1day

  • the changes of glucose metabolic levels after surgical management

    1day

  • Number of Participants with changes of kidney function levels after surgical management

    1 day

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

This study intends to include 200 patients diagnosed with primary aldosteronism undergoing surgery. An ACTH stimulation test will be performed within one week postoperatively. The participants will be aged 18-75 years, with no gender restrictions. Exclusion criteria include patients using medications that affect adrenal cortical function, patients with a history of adrenal surgery, pregnant or breastfeeding women, and patients with severe underlying diseases (such as liver or kidney failure) that may affect adrenal cortical function

You may qualify if:

  • Patients diagnosed with unilateral primary aldosteronism who undergo surgical treatment and have their cortical function assessed by an ACTH stimulation test within one week postoperatively.

You may not qualify if:

  • Patients using medications that affect adrenal cortical function.
  • Patients with a history of adrenal surgery
  • Pregnant or breastfeeding women
  • Patients with severe underlying diseases (such as liver or kidney failure) that may affect adrenal cortical function

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Biospecimen

Retention: SAMPLES WITHOUT DNA

patient serum

MeSH Terms

Conditions

Hyperaldosteronism

Condition Hierarchy (Ancestors)

Adrenocortical HyperfunctionAdrenal Gland DiseasesEndocrine System Diseases

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Target Duration
1 Year
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 27, 2024

First Posted

August 2, 2024

Study Start

August 15, 2024

Primary Completion

March 15, 2026

Study Completion (Estimated)

July 30, 2026

Last Updated

August 2, 2024

Record last verified: 2024-07

Data Sharing

IPD Sharing
Will share